Clinical Trial Update: Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy [EARLY_Phase 1]

View source ↗

Summary

Early-phase pilot trial of denosumab in BRCA1/2 mutation carriers scheduled for risk-reducing salpingo-oophorectomy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Carcinoma

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ovarian Carcinoma | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2022-06-14